Dr. Pengyi Liu | Medicine and Dentistry | Best Researcher Award
Doctoral student at Shanghai Ruijin Hospital, China
Dr. Pengyi Liu is a dedicated researcher specializing in the tumor immune microenvironment of pancreatic cancer. Currently pursuing a doctoral degree at Ruijin Hospital, Shanghai Jiaotong University, Liu’s work focuses on understanding the roles of macrophages and T cells in tumor progression. With a Bachelor’s degree in Clinical Medicine, Liu has consistently excelled academically, earning numerous honors, including multiple scholarships and recognition as an “Outstanding Graduate.” Their research has led to significant publications in high-impact journals, exploring novel mechanisms in pancreatic cancer, such as macrophage differentiation and immune response modulation. Proficient in various experimental techniques like cell culture, flow cytometry, and molecular biology, Liu demonstrates a broad skill set essential for cutting-edge cancer research. Their collaborative efforts and innovative approaches continue to advance the field, offering potential new targets for diagnosis and treatment. Liu’s work holds promise for improving clinical outcomes in pancreatic cancer patients.
Professional Profile
Education
Dr. Pengyi Liu’s educational journey reflects a strong foundation in clinical medicine and research. He completed his Bachelor’s degree in Clinical Medicine at Shanghai Jiaotong University from 2016 to 2021, achieving a commendable GPA of 3.63. During this time, Liu was recognized for his academic excellence, earning multiple scholarships and being named a “Merit Student” in 2020. After completing his undergraduate studies, Liu continued his education at Ruijin Hospital, affiliated with Shanghai Jiaotong University School of Medicine, where he is currently pursuing a Doctor of Surgery degree under the prestigious “Zhiyuan Honors Program.” His research is guided by Prof. Baiyong Shen, focusing on the molecular mechanisms of pancreatic cancer. In addition to his rigorous academic training, Liu has taken a wide range of courses, including Anatomy, Physiology, Molecular Biology, Immunology, and Laboratory Animal Science, providing him with a well-rounded knowledge base for his advanced research.
Professional Experience
Dr. Pengyi Liu’s professional experience is centered around groundbreaking research in the field of pancreatic cancer. Currently a doctoral candidate at Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Liu is engaged in advanced research on the tumor immune microenvironment, particularly the roles of macrophages and T cells in tumor progression. Under the mentorship of Prof. Baiyong Shen, Liu has contributed to numerous high-impact publications on pancreatic cancer, including studies on macrophage differentiation, immune modulation, and tumor progression. His research projects are multifaceted, encompassing both molecular and animal model-based approaches to uncover novel mechanisms and potential therapeutic targets. Liu is proficient in various laboratory techniques, including cell culture, flow cytometry, molecular biology assays, and the construction of patient-derived xenograft and organoid models. His work continues to shape the understanding of pancreatic cancer, offering new insights into its diagnosis, treatment, and the development of targeted therapies.
Research Interests
Dr. Pengyi Liu’s research interests are centered around the tumor immune microenvironment, with a particular focus on pancreatic cancer. His work aims to understand the complex interactions between immune cells, such as macrophages and T cells, and tumor progression. Liu is dedicated to uncovering the molecular mechanisms that drive pancreatic cancer, especially how immune cells contribute to the tumor environment and influence cancer growth. His research explores the roles of various molecules, including lncRNAs and signaling pathways, in shaping the immune response and tumor microenvironment. By studying the molecular and cellular processes in pancreatic cancer, Liu aims to identify potential therapeutic targets for better diagnosis and treatment strategies. Additionally, Liu’s work involves the development and use of advanced experimental models, such as patient-derived xenografts and organoids, to simulate the tumor environment and test new treatment approaches. His goal is to bridge the gap between basic research and clinical application in oncology.
Awards and Honors
Dr. Pengyi Liu has received numerous awards and honors throughout his academic career, reflecting his exceptional performance and dedication to research. He was awarded the prestigious scholarships of Shanghai Jiaotong University in 2017, 2018, 2019, and 2020, which recognize his academic excellence. In 2020, he was named a “Merit Student,” further highlighting his outstanding achievements. Dr. Liu’s dedication to his studies was also acknowledged when he was recognized as an “Outstanding Graduate” in 2021, a testament to his strong academic record and research contributions. Additionally, as a graduate student, he was awarded the First-Class Scholarship in 2022 and the Second-Class Scholarship in 2023, underscoring his continued academic excellence and research productivity. These accolades demonstrate not only his commitment to excellence but also the recognition he has earned from his peers and academic community for his hard work and significant contributions to the field of medical research.
Conclusion
Pengyi Liu’s academic achievements, extensive research experience, and significant contributions to understanding the tumor immune microenvironment in pancreatic cancer make them a strong contender for the Best Researcher Award. With a clear focus on advancing scientific knowledge and potential for real-world impact, Liu exemplifies the qualities of a leading researcher. Continued diversification of their research scope and greater emphasis on clinical applications could further amplify their contributions to the field.
Publications Top Noted
- Comprehensive analysis of KLF family reveals KLF6 as a promising prognostic and immune biomarker in pancreatic ductal adenocarcinoma
- Authors: Lin, J., Liu, P., Sun, K., Wang, T., Shen, B.
- Year: 2024
- Journal: Cancer Cell International
- Citations: 0
- Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication
- Authors: Chen, D., Liu, P., Lu, X., Li, H., Shen, B.
- Year: 2024
- Journal: Journal of Experimental and Clinical Cancer Research
- Citations: 0
- ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma
- Authors: Liu, Y., Cao, Y., Liu, P., Wang, W., Shen, B.
- Year: 2024
- Journal: Cellular Oncology
- Citations: 2
- BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1
- Authors: Cao, Y., Wang, X., Liu, Y., Jiang, L., Shen, B.
- Year: 2024
- Journal: Advanced Science
- Citations: 3
- CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization
- Authors: Liu, Y., Liu, P., Duan, S., Jiang, Y., Shen, B.
- Year: 2024
- Journal: Cell Death and Differentiation
- Citations: 0
- SNHG17 alters anaerobic glycolysis by resetting phosphorylation modification of PGK1 to foster pro-tumor macrophage formation in pancreatic ductal adenocarcinoma
- Authors: Lin, J., Liu, Y., Liu, P., Bao, H., Lin, J.
- Year: 2023
- Journal: Journal of Experimental and Clinical Cancer Research
- Citations: 0
- A microprotein N1DARP encoded by LINC00261 promotes Notch1 intracellular domain (N1ICD) degradation via disrupting USP10-N1ICD interaction to inhibit chemoresistance in Notch1-hyperactivated pancreatic cancer
- Authors: Zhai, S., Lin, J., Ji, Y., Deng, X., Shen, B.
- Year: 2023
- Journal: Cell Discovery
- Citations: 10
- Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment
- Authors: Wang, L., Liu, Y., Dai, Y., Chen, S., Shen, B.
- Year: 2023
- Journal: Gut
- Citations: 100
- LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma
- Authors: Liu, Y., Shi, M., He, X., Sun, B., Shen, B.
- Year: 2022
- Journal: Journal of Hematology and Oncology
- Citations: 76
